<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04281498</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 07-0548-0008</org_study_id>
    <secondary_id>P01CA108671</secondary_id>
    <secondary_id>MPN-RC 119</secondary_id>
    <nct_id>NCT04281498</nct_id>
  </id_info>
  <brief_title>Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation</brief_title>
  <official_title>A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Mascarenhas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Myeloproliferative Neoplasms Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The presence of IDH mutation is associated with worse survival in patients with&#xD;
      myelofibrosis. Moreover IDH mutations are among the most frequently encountered events in&#xD;
      MPNs that have progressed to acute myeloid leukemia. Ruxolitinib, a JAK1/2 inhibitor, and&#xD;
      enasidenib an IDH2 inhibitor are effective and tolerable treatments for patients with&#xD;
      myelofibrosis (MF) and acute myeloid leukemia (AML), respectively. The study team hypothesize&#xD;
      that the combination of these agents in patients with MPN with an IDH2 mutation will improve&#xD;
      the overall clinical response to therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At this time, there is no standard medical treatment for MPN-AP/BP and most patients with&#xD;
      accelerated and blast phase MPN do not respond well to treatment This is a phase II&#xD;
      open-label study to evaluate the safety and efficacy of combined ruxolitinib and enasidenib&#xD;
      in patients with accelerated/blast-phase myeloproliferative neoplasm or chronic phase&#xD;
      myelofibrosis with high risk features and IDH2 mutation.&#xD;
&#xD;
      Ruxolitinib (Jakafi/Jakavi) is FDA approved for myelofibrosis and was shown to reduce&#xD;
      splenomegaly and improve symptoms. Enasidenib is a potent inhibitor of the IDH2 mutant enzyme&#xD;
      and is FDA approved for relapsed refractory AML where it showed effectivity.&#xD;
&#xD;
      Pre-clinical studies indicate increased disease mitigating effects with the combination of&#xD;
      enasidenib and ruxolitinib.&#xD;
&#xD;
      This study will enroll up to 32 patients. Ruxolitinib and enasidenib will be given orally in&#xD;
      28-day cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Arm open-label Study of Combined Ruxolitinib and Enasidenib in Patients with Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis with an IDH2 Mutation, Simons minimax design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of MPN participants with response</measure>
    <time_frame>6 Months</time_frame>
    <description>The proportion of treated accelerated-phase and blast-phase MPN patients (primary cohort) that achieve a best response of either complete response (CR), Partial Response (PR), or complete response with incomplete recovery of counts (CRi), when treated with the combination of ruxolitinib with enasidenib within 6 cycles of combined therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of MPN participants with blast response</measure>
    <time_frame>6 Months</time_frame>
    <description>The proportion of treated accelerated-phase and blast-phase MPN patients that achieve complete (CBR) and partial blast response (PBR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of MF-CP participants with any response</measure>
    <time_frame>6 Months</time_frame>
    <description>The proportion of treated patients with MF-CP and 4%-9% circulating blasts that achieve complete response (CR) Partial Response (PR), clinical improvement (CI) with the combination of ruxolitinib and enasidenib within 6 cycles of combined therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Accelerated/Blast-phase Myeloproliferative Neoplasm</condition>
  <condition>Chronic-phase Myelofibrosis</condition>
  <condition>IDH2 Mutation</condition>
  <arm_group>
    <arm_group_label>Patients with MPN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib and Enasidenib combination therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Patients who are on ruxolitinib will continue their current dose. Patients who are not on ruxolitinib will receive ruxolitinib dosing based on platelet count</description>
    <arm_group_label>Patients with MPN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enasidenib</intervention_name>
    <description>50mg -100mg daily</description>
    <arm_group_label>Patients with MPN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Subjects must be ≥ 18 years at the time of signing the Informed Consent Form (ICF).&#xD;
&#xD;
          -  Understanding and voluntary signing an IRB-approved informed consent form.&#xD;
&#xD;
          -  Diagnosis of:&#xD;
&#xD;
               1. Accelerated-phase (≥ 10% blasts in PB or BM) or blast-phase (≥ 20% blasts in PB&#xD;
                  or BM) myeloproliferative neoplasm (with history of prior myelofibrosis,&#xD;
                  polycythemia vera, or essential thrombocythemia)&#xD;
&#xD;
               2. Previously treated patients with myelofibrosis with persistent disease or&#xD;
                  progressive disease (persistent or progressive splenomegaly, leukocytosis,&#xD;
                  anemia, or thrombocytopenia) with intermediate-1 or greater risk disease&#xD;
                  according to 2013 International Working Group (IWG) criteria, and 4-9%&#xD;
                  circulating blasts.&#xD;
&#xD;
          -  Demonstration of an IDH2 mutation.&#xD;
&#xD;
          -  Platelet count &gt; 75,000 X 109/L for chronic phase myelofibrosis patients.&#xD;
&#xD;
          -  Prior therapy with either ruxolitinib or enasidenib is permitted, but not a&#xD;
             combination of ruxolitinib and enasidenib.&#xD;
&#xD;
          -  Patients with chronic phase myelofibrosis on ruxolitinib must be on the drug for at&#xD;
             least 3 months and on a stable dose for at least one month.&#xD;
&#xD;
          -  Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
             0 to 2. ECOG 3 status will be allowed if attributable to MPN.&#xD;
&#xD;
          -  Patients must have adequate organ function as demonstrated by the following: a. Direct&#xD;
             bilirubin &lt; 2.0mg/dL, unless due to Gilbert's disease or current elevations in direct&#xD;
             bilirubin associated with existing enasidenib use. b. Serum creatinine&lt; 2.0 mg/dL. c.&#xD;
             ALT and AST ≤ 3x upper limit of normal (unless transaminitis is considered to be&#xD;
             related to MF).&#xD;
&#xD;
          -  Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy&#xD;
             test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to starting&#xD;
             enasidenib and must either commit to continued abstinence from heterosexual&#xD;
             intercourse or begin TWO acceptable methods of birth control, one highly effective&#xD;
             method and one additional effective method AT THE SAME TIME, at least 4 weeks before&#xD;
             she starts taking enasidenib. FCBP must also agree to ongoing pregnancy testing. Men&#xD;
             must agree to use a condom during sexual contact with a female of child bearing&#xD;
             potential even if they have had a successful vasectomy. All patients must be counseled&#xD;
             at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.&#xD;
&#xD;
          -  All study participants must be able to swallow oral medication.&#xD;
&#xD;
          -  Ability to adhere to the study visit schedule and all protocol requirements.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Use of any other standard anti-neoplastic drug or growth factor (e.g., anagrelide,&#xD;
             G-CSF, lenalidomide, thalidomide clofarabine) except hydroxyurea or experimental&#xD;
             drugs, with the exception of ruxolitinib or enasidenib, less than 14 days or&#xD;
             5-half-lives, whichever is longer, prior to starting study therapy and/or lack of&#xD;
             recovery from all toxicity (except for alopecia) from previous therapy to Grade 1 or&#xD;
             better.&#xD;
&#xD;
             a. Patients will be permitted to receive hydroxyurea while on study for up to a total&#xD;
             of 3 cycles of combined therapy.&#xD;
&#xD;
          -  Known prior clinically relevant hypersensitivity reaction to ruxolitinib or&#xD;
             enasidenib.&#xD;
&#xD;
          -  Prior therapy with enasidenib in combination with ruxolitinib.&#xD;
&#xD;
          -  Concurrent use of strong inducers of CYP3A4 (Rifampin, St. John's Wort, Carbamazepine,&#xD;
             Phenytoin) and/or the following strong inhibitors of CYP3A4 (protease inhibitor&#xD;
             containing HIV anti-retrovirals, cobicistat, clarithromycin, itraconazole,&#xD;
             ketoconazole, nefazodone, and telithromycin) are prohibited. Also prohibited are&#xD;
             CYP2C9 substrate medications that have a narrow therapeutic range: phenytoin and&#xD;
             warfarin.&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent form, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study or which&#xD;
             confounds the ability to interpret data from the study.&#xD;
&#xD;
          -  Lactating females.&#xD;
&#xD;
          -  Active uncontrolled infections.&#xD;
&#xD;
          -  Patients with active malignancy of other type than required for this study are not&#xD;
             eligible with the exception of currently treated basal cell, squamous cell carcinoma&#xD;
             of the skin, or carcinoma &quot;in situ&quot; of the cervix or breast. Patients with&#xD;
             malignancies with indolent behavior such as prostate cancer treated with radiation or&#xD;
             surgery can be enrolled in the study as long as they have a reasonable expectation to&#xD;
             have been cured with the treatment modality received.&#xD;
&#xD;
          -  Subject has significant active cardiac disease within 6 months prior to the start of&#xD;
             study treatment, including New York Heart Association (NYHA) Class III or IV&#xD;
             congestive heart failure; acute coronary syndrome (ACS); and/or stroke; or left&#xD;
             ventricular ejection fraction (LVEF) &lt; 40% by echocardiogram (ECHO) or multi-gated&#xD;
             acquisition (MUGA) scan obtained within 28 days prior to the start of study treatment.&#xD;
&#xD;
          -  QTc interval (Fridericia's correction [QTcF]) &gt; 450 ms&#xD;
&#xD;
        All inclusion and exclusion criteria will be reviewed by the Investigator or qualified&#xD;
        designee to ensure that the patient qualifies for the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Mascarenhas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruben Mesa, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mays Cancer Center at UT Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Hoffman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michal Bar-Natan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michal Bar-Natan, MD</last_name>
    <phone>212-241-6772</phone>
    <email>michal.bar-natan@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raajit Rampal, MD, PhD</last_name>
    <phone>212-639-2194</phone>
    <email>rampalr@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeanne Palmer, MD</last_name>
      <email>Palmer.Jeanne@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jeanne Palmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronald Paquette, MD</last_name>
      <phone>310-423-1160</phone>
      <email>ronald.paquette@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Ronald Paquette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew T. Kuykendall, MD</last_name>
      <phone>813-745-6841</phone>
      <email>Andrew.Kuykendall@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Andrew T. Kuykendall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abdulraheem Yacoub, MD</last_name>
      <phone>913-588-6029</phone>
      <email>ayacoub@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Abdulraheem Yacoub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Rogel Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5936</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristen Pettit, MD</last_name>
      <phone>734-764-8195</phone>
      <email>krpettit@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Kristen Pettit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lonette Sandy</last_name>
      <phone>212-241-4546</phone>
      <email>Lonette.Sandy@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amelia Gabler, BS</last_name>
    </contact_backup>
    <investigator>
      <last_name>Michal Bar-Natan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raajit Rampal, MD, PhD</last_name>
      <phone>212-639-2194</phone>
      <email>rampalr@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Raajit Rampal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rupali Roy Bhave, MD</last_name>
      <phone>336-716-1808</phone>
      <email>rbhave@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Rupali Roy Bhave, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taussig Cancer Center Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Gerds, MD, MS</last_name>
      <phone>216-445-9840</phone>
      <email>gerdsa@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Aaron Gerds, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mays Cancer Center at UT Health San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruben Mesa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ruben Mesa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vikas Gupta, MD, FRCP, FRCPath</last_name>
      <phone>(416) 946-4521</phone>
      <email>vikas.gupta@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Vikas Gupta, MD, FRCP, FRCPath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>John Mascarenhas</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Phase II</keyword>
  <keyword>Myelofibrosis</keyword>
  <keyword>Therapeutic</keyword>
  <keyword>Ruxolitinib</keyword>
  <keyword>Enasidenib</keyword>
  <keyword>IDH2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

